CMCéline Mouly

Céline Mouly

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Céline Mouly has a total of 65 co-authors. Here are the top co-authors by number of shared publications:

  • A. Pequignot

    Chirurgie thoracique, CHU d'Amiens, Amiens, France

    1 shared publication
  • Agnès Linglart

    Department of Paediatric Endocrinology, Diabetology and Severe Obesity, Bicêtre Hospital, Paris, France

    1 shared publication
  • Alexandre Buffet

    Department of Endocrinology, Larrey Hospital, CardioMet Institute, University Hospital Centre of Toulouse, Toulouse, France

    1 shared publication
  • Anne Barlier

    Aix Marseille Univ, APHM, INSERM, MMG, MarMaRa institute, La Timone University Hospital, Laboratory of Molecular Biology GEnOPé, BIOGENOPOLE, Marseille, France

    1 shared publication
  • Anne Lienhardt

    Department of Medical Paediatrics, University Hospital Centre of Limoges, Limoges, France

    1 shared publication
  • Anne Vincent-Salomon

    Institut Curie, PSL University

    1 shared publication

Latest Publications

  • Beyond MEN1, When to Think About MEN4? Retrospective Study on 5600 Patients in the French Population and Literature Review

    by Benjamin Chevalier, Lucie Coppin, Pauline Romanet, Thomas Cuny, Jean-Christophe Maïza, Juliette Abeillon, Julien Forestier, Thomas Walter, Olivier Gilly, Maëlle Le Bras, et al.

    Context Germline CDKN1B variants predispose patients to multiple endocrine neoplasia type 4 (MEN4), a rare MEN1-like syndrome, with CDKN1B mutations are frequently suggested to explain cases of genetically-negative MEN1, the prevalence and phenotype of MEN4 patients is poorly known, and genetic counseling is unclear. Objective To evaluate the prevalence of MEN4 in MEN1-suspected patients and characterize the phenotype of MEN4 patients. Design Retrospective observational nationwide study. Narrative review of literature and variant class reassessment. Patients We included all adult patients with class 3/4/5 CDKN1B variants identified by the laboratories from the French TENGEN network between 2015 and 2022 through germline genetic testing for MEN1 suspicion. After class reassessment, we compared the phenotype of symptomatic patients with class 4/5 CDKN1B variants, i.e. with genetically-confirmed MEN4 diagnosis, in our series and in literature with 66 matched MEN1 patients from the UMD-MEN1 database. Results From 5600 MEN1-suspected patients analyzed, four patients with class 4/5 CDKN1B variant were found (0.07%). They presented with multiple duodenal NET, PHPT and adrenal nodule, isolated PHPT, PHPT and pNET. We listed 29 patients with CDKN1B class 4/5 variants from literature. Compared to matched MEN1 patients, MEN4 patients presented lower NET incidence and older age at PHPT diagnosis. Conclusion The prevalence of MEN4 is low. PHPT and PA represent the main associated lesions, NETs are rare. Our results suggest a milder and later phenotype than in MEN1. Our observations will help to improve genetic counseling and management of MEN4 families.


  • Clinical characteristics of familial hypocalciuric hypercalcaemia type 1: A multicentre study of 77 adult patients

    by Céline Mouly, Rosa Vargas‐Poussou, Anne Lienhardt, Caroline Silve, Marguerite Hureaux, Corinne Magdelaine, Alexandre Buffet, Solange Grunenwald, Jean-Marc Kuhn, Thierry Brue, et al.

    Objective: Familial hypocalciuric hypercalcaemia type 1 (FHH1), related to heterozygous loss‐of‐function mutations of the calcium‐sensing receptor gene, is the main differential diagnosis for primary hyperparathyroidism. The aim of our study was to describe clinical characteristics of adult patients living in France with a genetically confirmed FHH1.Design and patients: This observational, retrospective, multicentre study included 77 adults, followed up in 32 clinical departments in France, with a genetic FHH1 diagnosis between 2001 and 2012.Results: Hypercalcaemia was diagnosed at a median age of 53 years [IQR: 38‐61]. The diagnosis was made after clinical manifestations, routine analysis or familial screening in 56, 34 and 10% of cases, respectively, (n = 58; data not available for 19 patients). Chondrocalcinosis was present in 11/51 patients (22%), bone fractures in 8/56 (14%) and renal colic in 6/55 (11%). The median serum calcium was 2.74 mmol/L [IQR: 2.63‐2.86 mmol/L], the median plasma parathyroid hormone level was 4.9 pmol/L [3.1‐7.1], and the median 24‐hour urinary calcium excretion was 2.8 mmol/24 hours [IQR: 1.9‐4.0]. Osteoporosis (dual X‐ray absorptiometry) or kidney stones (renal ultrasonography) were found in 6/38 patients (16%) and 9/32 patients (28%), respectively. Fourteen patients (18%) underwent parathyroid surgery; parathyroid adenoma was found in three patients (21%) and parathyroid hyperplasia in nine patients (64%). No correlation between genotype and phenotype was established.Conclusion: This large cohort study demonstrates that FHH1 clinical characteristics can be atypical in 33 patients (43%). Clinicians should be aware of this rare differential diagnosis in order to adopt an appropriate treatment strategy.


  • L’incontinence des cordes vocales est un nouveau facteur de risque de survenue de pneumopathies postopératoires en chirurgie carcinologique pulmonaire

    by C. Laude, F. De Dominicis, A. Pequignot, C. Blot, C. Mouly, M. Bensussan, A. Salomon, G. Merlusca, H. Dupont, P. Berna, et al.